XLON
EDEN
Market cap25mUSD
Oct 09, Last price
2.35GBP
1D
0.00%
1Q
-15.79%
Jan 2017
-79.10%
IPO
-87.67%
Name
Eden Research PLC
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Eden BioSolutions Plc offers sustainable solutions for crop protection, animal health and consumer products in the United Kingdom and rest of Europe. The firm provides various plant protection products, such as foliar disease control, soil pest, protected glass house crops, and post-harvest applications. It also offers treatment for various pathogens that effect animal health, as well as provides animal health products, such as shampoos, conditioners, odour controls, flea and tick controls, hygiene products, parasite treatments, and insect sprays. The company also offers human health products comprising head-lice, fragrances, wound-care, and food flavorings. It provides a range of natural and synthetic active ingredients, including pesticides, as well as biocides. The company was founded on June 22, 1995 and is headquartered in Abingdon, the United Kingdom.
Key people
Tom G. Lupton
Non-Executive Chairman of the Board · since 2014
Alex J. Abrey
Chief Financial Officer, Executive Director · since 2009
Sean M Smith
Chief Executive Officer, Executive Director · since 2014
Michael Carroll
Director of Regulatory Affairs · since 2020
Robin E. Sims
Company Secretary
Legal address
6, PRIORY COURT
PRIORY COURT BUSINESS PARK
CIRENCESTER, GLS GL7 5JB
GB
PRIORY COURT BUSINESS PARK
CIRENCESTER, GLS GL7 5JB
GB
Headquarters
6, PRIORY COURT
PRIORY COURT BUSINESS PARK
Poulton
CIRENCESTER, GLS GL7 5JB
GB
PRIORY COURT BUSINESS PARK
Poulton
CIRENCESTER, GLS GL7 5JB
GB
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||